NAGE (ChromaDex Corp.) Market Value to Book Value Ratio

niagenbioscience.com (NAGE) - corporate logo

This daily price chart for Chromadex Corp (NAGE) represents a company developing advanced medical devices and longevity products based on scientific research. The asset metric is 2.37. The business relies on unique patent control over Niagen and exclusive raw material supplies; however, low barriers to entry in the dietary supplement sector create risks due to a multitude of small players.

NAGE - ChromaDex Corp Market-to-Book Ratio over the range 03/20/2025 - 10/28/2026

NAGE (niagenbioscience.com): analytical breakdowns and indicator data

- price and consensus price forecast:
Stock Price ChromaDex Corporation|NAGE - Average Forecast Price
- market capitalization data:
Market Value Niagen|NAGE - Real Price to Acquire Entire Company
- book capitalization data:
Book Value per Share ChromaDex|NAGE - Total Stockholders' Equity|Market Capitalization to Book Value Ratio niagenbioscience.com|NAGE - Total Business Assets
- debt and liquidity data:
Total Debt to Capital Chromadex Corp|NAGE - Ratio of Long-Term Indebtedness to Capital|Short-Term Debt to Capital ChromaDex|NAGE - Company Total Debt|Debts to Book Capitalization Niagen
Initial company analysis:ChromaDex Corp - NAGE
Manufactured products of niagenbioscience.com

For Chromadex Corp (NAGE), which seeks dominance in the NAD+ segment via Niagen, the price-to-book ratio history reflects the market's valuation of its intellectual property potential relative to net assets. Sharp spikes in this ratio signal a business revaluation driven by external shocks, allowing investors to distinguish a fair innovation premium from the risks of capital degradation.

Direct competitors

Market Capitalization to Book Value Ratio ISRG|DHR (danaher.com) - Market-to-Book Ratio|Market Value to Book Value Ratio BDX|Market Cap to Net Assets Ratio STERIS PLC|West Pharmaceutical Services Inc - Market Capitalization to Book Value Ratio|Market-to-Book Ratio Baxter Healthcare (BAX)|MASI - Market Capitalization to Book Value Ratio|Capitalization to Book Value Ratio stevanatogroup.com STVN|Market Capitalization to Book Value Ratio TFX (Teleflex)|MMSI - Market Capitalization to Book Value|NVST (Envista Holdings Corp) - Market Capitalization to Book Value Ratio|ICU Medical Inc. (ICUI) - Market Cap to Net Assets Ratio|XRAY (DENTSPLY SIRONA Inc.) - Market Capitalization to Book Value Ratio|Market Capitalization to Book Value Ratio LMAT|Market Value to Book Value Ratio AtriCure (ATRC)|Market Value to Book Value Ratio STAAR Surgical Co. STAA|Market Cap to Net Assets Ratio ZimVie Dental|Market Value to Book Value AngioDynamics Inc. ANGO|Market Capitalization to Book Value Ratio CERS (Cerus Corporation)|TKNO: Market Capitalization to Book Value|Market Value to Book Value Ratio Monogram Orthopedics|STSS (Sharps Technology) - Capitalization to Book Value Ratio|INFU: Market Value to Book Value Ratio|Market Capitalization to Book Value Utah Med (UTMD)|Market Cap to Net Assets Ratio KORU Medical Systems|Market Cap to Book Value Multiple NYXH (nyxoah.com)|Market Value to Book Value Ratio Microbot Medical|PDEX - Market Value to Book Value|Zentek Limited - Market Cap to Net Assets Ratio|ELUT: Market Capitalization to Book Value Ratio|MLSS (Milestone Scientific) - Market Value to Book Value Ratio|nexgel.com (NXGL) - Market Cap to Net Assets Ratio|Market Capitalization to Book Value Ratio RVP (Retractable Technologies Inc.)|Market-to-Book Ratio HBIO|Market Value to Book Value Ratio Femasys Corp FEMY|Capitalization to Book Value Ratio meihuamed.com MHUA|Market Cap to Net Assets Ratio Predictive Oncology Inc. (POAI)|Callan JMB Inc. - Market Cap to Book Value Multiple|Market Value to Book Value Ratio ATRI (Atrion)|NURO - Market Capitalization to Book Value